Hepatobiliary disease in patients with cystic fibrosis

Current Opinion in Gastroenterology

Volumn 25, Issue 3, 2009, Pages 272-278

  Moyer, Katie ^a   Balistreri, William ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b MLC 3021 ^*  (United States)

Author keywords

Cystic fibrosis; Hepatobiliary disease; Liver disease

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

BILIARY CIRRHOSIS; CYSTIC FIBROSIS; DISEASE ASSOCIATION; HEPATOBILIARY DISEASE; HUMAN; LIFE EXPECTANCY; LIVER FAILURE; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; QUALITY OF LIFE; REVIEW; SURVIVAL;

ANIMALS; BILE DUCT DISEASES; CYSTIC FIBROSIS; HUMANS; LIVER DISEASES; RISK FACTORS;

EID: 67651099218     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283298865     Document Type: Review

References (56)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001.
2. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006; 173:475-482.
3. Wilschanski M. Patterns of gastrointestinal disease associated with mutations of CFTR. Curr Gastroenterol Rep 2008; 10:316-323. Review of current gastrointestinal manifestations of cystic fibrosis with a special emphasis on the genetics of the disease.
4. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Sem Liv Disease 2001; 21:471-488. (Pubitemid 33131040)
5. Cystic Fibrosis Foundation. Patient registry 2003: annual report to the Center Directors. Bethesda, Maryland: Cystic Fibrosis Foundation; 2004.
6. Chen AH, Innis SM, Davidson AG, et al. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am J Clin Nutr 2005; 81:686-691.
7. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30:1151-1158. (Pubitemid 29510852)
8. Patton HM, Sirlin C, Behling C, et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006; 43:413-427 [and Pinto HC, Carniero de Moura M, Day CP. Nonalcoholic steatohepatitis from cell biology to clinical practice. J Hepatol 2006; 44:197-208]. (Pubitemid 44568999)
9. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073. (Pubitemid 19231814)
10. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992; 68:809-818.
11. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67:117-133.
12. Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol 2002; 160:1705-1715.
13. Cohn JA, Strong TA, Picciotto MA, et al. Localization of CFTR in human bile duct epithelial cells. Gastroenterology 1993; 105:1857-1864.
14. Fitz JG, Basavappa S, McGill J, et al. Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest 1993; 91:319-328. (Pubitemid 23037287)
15. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7:179-196.
16. Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics 1999; 103:52-57. (Pubitemid 29281928)
17. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372:415-417. This study identifies defective bicarbonate transport as an important contributor to abnormal mucin production in cystic fibrosis.
18. Pier GB. Dropping acid to help cystic fibrosis. Nat Med 2008; 14:367-369.
19. Freudenberg F, Broderick AL, Yu BB, et al. Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am J Physiol Gastrointest Liver Physiol 2008; 294:G1411-G1420. Employing a mouse model carrying the ΔF508 gene mutation, this study identifies increased fecal bile acid loss and hyperbilirubinemia as a contributor to enhanced B-glucuronidase activity and subsequent damage to intrahepatic bile ducts.
20. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008; 321: 1837-1841. This is the first model of cystic fibrosis in newborn pigs. Newborn pigs with disrupted CFTR gene exhibit defective chloride transport and developed meconium ileus, exocrine pancreatic destruction, and FBC, very similar to abnormalities seen in newborn humans with cystic fibrosis.
21. Minagawa N, Nagata J, Shibao K, et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007; 133:1592-1602. ATP stimulates cholangiocyte secretion of bicarbonate through activation of CFTR and non-CFTR Cl- channels. (Pubitemid 350029742)
22. Fiorotto R, Spirli C, Fabrisi L, et al. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007; 133:1603-1613. This article further elucidates the mechanisms of action of UDCA on cholangiocyte fluid secretion. (Pubitemid 350029752)
23. Woo K, Dutta AK, Patel V, et al. Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl- transport in biliary epithelial cells through a PKCzeta-dependent pathway. J Physiol 2008; 586:2779-2798. (Pubitemid 351761791)
24. Diwakar V, Pearson L, Beath S. Liver disease in children with cystic fibrosis. Paediatr Respir Rev 2001; 2:340-349. (Pubitemid 34467151)
25. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994; 124:393-399. (Pubitemid 24094449)
26. Colombo C, Battezati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36:1374-1382. (Pubitemid 35403528)
27. Corbett K, Kelleher S, Rowland M, et al. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr 2004; 145:327-332. (Pubitemid 39165680)
28. Lindblad A, Glaumann H, Strandvik B.Atwo-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998; 27:166-174. (Pubitemid 28041550)
29. Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 7: 537-542. This retrospective review is significant in that it is the first large study reporting on long-term outcomes and natural history in patients with cystic fibrosis over age 40.
30. Desmond CP, Wilson J, Bailey M, et al. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int 2007; 27:1402-1408. This large retrospective review outlines the course of liver disease in adults with cystic fibrosis. (Pubitemid 350142255)
31. Gooding I, Dondos V, Gyi KM, et al. Variceal hemorrhage and cystic fibrosis: outcomes and implications for liver transplantation. Liver Transpl 2005; 11:1522-1526. (Pubitemid 43072628)
32. Comeau AM, Accurso FJ, White TB, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007; 119:e495-e518.
33. Mishra A, Greaves R, Smith K, et al. Diagnosis of cystic fibrosis by sweat testing: age-specific reference intervals. J Pediatr 2008; 53:758-763. This study identifies age-specific intervals for sweat electrolytes from childhood to adulthood.
34. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153:S4-S14. Consensus guidelines for the diagnosis of cystic fibrosis using a combination of clinical presentation, laboratory testing, and genetics.
35. Potter CJ, Fishbein M, Hammond S, et al. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? J Pediatr Gastroenterol Nutr 1997; 25:32-36.
36. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007; 13:529-536.
37. Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol 2007; 61:11-17. This review focuses on recent advances in imaging modalities used in the diagnosis of cystic fibrosis-associated liver disease.
38. Chaudry G, Navarro OM, Levine DS, et al. Abdominal manifestations of cystic fibrosis in children. Pediatr Radiol 2006; 36:233-240.
39. Feigelson J, Anagnostopoulos C, Poquet M, et al. Liver cirrhosis in cystic fibrosis: therapeutic implications and long term follow up. Arch Dis Child 1993; 68:653-657. (Pubitemid 23153249)
40. Ruzal-Shapiro C. Cystic fibrosis. An overview. Radiol Clin North Am 1998; 36:143-161.
41. Durieu I, Pellet O, Simonot L, et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999; 30:1052-1056. (Pubitemid 29278749)
42. Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23:1484-1490. (Pubitemid 26181232)
43. Galabert C, Montet JC, Lengrand D, et al. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992; 121:138-141.
44. Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 1997; 130:52-58. (Pubitemid 27492719)
45. Smith JL, Lewindon PJ, Hoskins AC, et al. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology 2004; 39:1673-1682.
46. Pozler O, Krajina A, Vanicek H, et al. Transjugular intrahepatic portosystemic shunt in five children with cystic fibrosis: long-term results. Hepatogastroenterology 2003; 50:1111-1114. (Pubitemid 36723853)
47. Linnane B, Oliver MR, Robinson PJ. Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series. Arch Dis Child 2006; 91:771-773. (Pubitemid 44351179)
48. Louis D, Duc ML, Reix P, et al. Partial splenectomy for portal hypertension in cystic fibrosis related liver disease. Pediatr Pulmonol 2007; 42:1173-1180. The middle-term and long-term effects of partial splenectomy on portal hypertension and its complications in patients with cystic fibrosis associated liver disease.
49. Milkiewicz P, Skiba G, Kelly D, et al. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol 2002; 17:208-213. (Pubitemid 34415676)
50. Ikegami T, Sanchez EQ, Uemara T, et al. Liver transplantation for cystic fibrosis in adults. Surg Today 2008; 38:26-29. (Pubitemid 350292599)
51. Mekeel KL, Langham MR Jr, Gonzalez-Peralta R, et al. Combined en bloc liver pancreas transplantation for children with CF. Liver Transpl 2007; 13:406-409. (Pubitemid 46605851)
52. Sharp HL. Cystic fibrosis liver disease and transplantation. J Pediatr 1995; 127:944-946.
53. Grannas G, Niepp M, Hopper MM, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation 2008; 85:524-531.
54. Storey S, Wald G. Novel agents in cystic fibrosis. Nat Rev Drug Discov 2008; 7:555-556. This article describes several new pharmacologic agents for the treatment of cystic fibrosis in phase I-III clinical trials.
55. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719-727. This study describes the outcomes of a phase II trial evaluating the effectiveness of PTC124 on CFTR-mediated transport in patients with cystic fibrosis and nonsense mutations.
56. Stalvey MS, Torrez DM, Hillan J, et al. Growth hormone therapy improves growth in children with cystic fibrosis related liver disease. J Pediatric Endocrinol Metabol 2008; 21:793-797.